Seer Stock (NASDAQ:SEER)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.32

52W Range

$1.51 - $2.63

50D Avg

$2.22

200D Avg

$1.93

Market Cap

$136.51M

Avg Vol (3M)

$258.59K

Beta

1.46

Div Yield

-

SEER Company Profile


Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

147

IPO Date

Dec 04, 2020

Website

SEER Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Grant$1.10M$223.00K-
Service-$913.00K$500.00K
Related Party-$5.21M$2.32M
Grant and Other-$808.00K-
Product-$8.56M$3.58M

Fiscal year ends in Dec 23 | Currency in USD

SEER Financial Summary


Dec 23Dec 22Dec 21
Revenue$16.66M$14.69M$6.39M
Operating Income$-103.46M$-97.23M$-71.47M
Net Income$-86.28M$-88.70M$-68.63M
EBITDA$-103.46M$-92.97M$-71.15M
Basic EPS$-1.35$-1.42$-1.13
Diluted EPS$-1.35$-1.42$-1.13

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 06, 24 | 9:00 PM
Q2 24Aug 08, 24 | 8:05 PM
Q1 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
CGEMCullinan Oncology, Inc.
QSIQuantum-Si incorporated
GBIOGeneration Bio Co.
NRIXNurix Therapeutics, Inc.
KYMRKymera Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
ORICORIC Pharmaceuticals, Inc.
FHTXFoghorn Therapeutics Inc.
MLYSMineralys Therapeutics, Inc.
HCWBHCW Biologics Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
MNOVMediciNova, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
LYELLyell Immunopharma, Inc.
STTKShattuck Labs, Inc.
PHVSPharvaris N.V.
NKTXNkarta, Inc.
MOLNMolecular Partners AG